27 results about "Sulfatase" patented technology

To provide formulations of protein molecules comprising iduronate 2-sulfatase.SOLUTION: Certain embodiments provide a pharmaceutical composition comprising a protein molecule comprising an ERT enzyme-Fc fusion polypeptide and a modified Fc polypeptide, a buffer, an isotonicity agent, a surfactant, and a stabilizer, wherein the pH of the pharmaceutical composition is about 5.5 to 7.0, and further provide methods of use thereof. In certain embodiments, the buffer is selected from the group consisting of phosphate buffer, acetate buffer, arginine buffer, and histidine buffer. In certain embodiments, the phosphate buffer is a sodium phosphate buffer or a potassium phosphate buffer.SELECTED DRAWING: None

The invention discloses a biomarker, application of the biomarker in predicting the risk of diabetic nephropathy and a kit, which can realize non-invasive efficient evaluation on the severity of diabetic nephropathy and provide important supplement for early diagnosis and refined risk stratification of diabetic nephropathy. The ratio of the Sulfatase-1 to the creatinine Cr is uSULF1 / Cr, and the Sulfatase-1 and the creatinine Cr are both from urine.

Certain embodiments provide a fusion protein comprising an iduronate 2-sulfatase (IDS) amino acid sequence, an IDS variant amino acid sequence, or a catalytically active fragment thereof; and an anti-transferrin receptor (TfR) antibody as described herein, as well as methods of use thereof.

Certain embodiments provide a pharmaceutical composition comprising: a protein molecule comprising an ERT enzyme-Fc fusion polypeptide and a modified Fc polypeptide; a buffer; an isotonicity agent; a surfactant; and a stabilizer; wherein the pH of the pharmaceutical composition is about 5.5 to 7.0, as well as methods of use thereof.

The present invention relates to a pharmaceutical composition for CNS delivery of high-concentration heparan N-sulfatase (HNS) with improved stability, and a pharmaceutical dosage form containing the same. The pharmaceutical composition and pharmaceutical dosage form containing the same according to the present invention have excellent dosage form stability, such as reduced turbidity and significantly improved purity, and are therefore useful in enzyme replacement therapy (ERT) for the treatment of mucopolysaccharidosis type III.

The present application belongs to the technical field of microbial inoculants, and particularly relates to a Phocaediola doleeri, and further discloses a use of the Phocaediola doleeri in preparing a product for preventing and treating glycolipid metabolic disorder. A YG0564 strain is screened from healthy adult feces, and is identified as the Phocaediola doleeri and classified and named as Phocaediola doleeri. The Phocaediola doleeri strain YG0564 contains cholesteryl sulfatase, and can significantly reduce blood fat and blood sugar in vivo and in vitro, and can obviously prevent and treat obesity and glycolipid metabolic disorder.

The present invention relates to a pharmaceutical composition for preventing or treating Sanfilippo syndrome type A (MPS IIIA) comprising heparan N-sulfatase (HNS), and more particularly, to an optimal dose and period of administration of heparan N-sulfatase, which can effectively reduce the accumulation of heparan sulfate (HS) while improving the cognition of patients. According to the present invention, it can be used as enzyme replacement therapy (ERT) for treating Sanfilippo syndrome type A.

This invention provides a method for synthesizing the compound DDAO-Sulfate, belonging to the field of chemical synthesis technology. The method includes the following steps: mixing DDAO and sodium ethoxide with anhydrous dimethylformamide to obtain a mixed solution; adding pyridine sulfur trioxide to the mixed solution and heating and stirring the reaction under light-protected conditions; subsequently concentrating under vacuum to obtain a residue; and purifying the residue by column chromatography using an eluent to obtain the final product. This synthetic method effectively improves the yield while selecting and optimizing the reactants, avoiding the use of easily deteriorated reagents and interference caused by the introduction of irrelevant substances, thus providing an efficient pathway for the preparation of fluorescent detection probes for sulfatase.

The invention discloses a TE enzyme mutant with improved activity and application thereof, and belongs to the technical field of biology. Schrodinger molecular docking is combined with fixed-point saturation mutation to establish a mutant library, Rosetta is used for screening the mutant library, searching a target point and carrying out single-point mutation and combined mutation, the activity of thioesterase is improved, the synthesis efficiency of Surfactin is further improved, and a production strain with better fermentation performance in industrial production is obtained. Through verification, mutations comprise A113W, A113G, K122H, K192D and a combination of the A113W, the A113G, the K122H and the K192D, fermentation verification shows that the yield of the Surfactin is increased by 41.2% to the maximum compared with that of a wild type and reaches 9.6 g / L, thioesterase with higher activity and a production strain with better fermentation performance in industrial production are obtained, and powerful support is provided for efficient production of the Surfactin.

This disclosure relates to a liquid thiosynergist, to an antioxidant composition comprising the same, to a polymer composition comprising the antioxidant composition, to use of the antioxidant composition for stabilizing polymer, and to a process of synthesizing the liquid thiosynergist.

The present invention provides compositions used for the treatment and / or prevention of protein aggregation disorders. [Solution] Proteopathy encompasses a wide range of ailments, including neurodegenerative diseases (e.g., polyglutamine diseases such as huntingtin in Alzheimer's disease, Parkinson's disease, and Huntington's disease, and prion diseases); amyloidosis of other non-neuronal proteins (especially I1-antitrypsin, immunoglobulin light and heavy chains, lactadherin, apolipoprotein, gelzolin, lysozyme, fibrinogen, atrial natriuretic factor, keratin, lactoferrin, and β-2 microglobulin, etc.); sickle cell disease; cataracts; cystic fibrosis; retinitis pigmentosa; and nephrogenic diabetes insipidus. Administration of sulfatase inhibitors is generally suitable for treating and / or preventing protein toxicity associated with proteopathy. Therefore, the present invention provides compositions comprising sulfatase inhibitors for the treatment of proteopathy.

The application discloses a kind of biological enzyme deodorization antibacterial agent for sewage treatment, including: biological complex enzyme preparation 10~30 parts by weight, probiotic preparation 5~15 parts by weight, carrier 40~70 parts by weight, auxiliary agent 1~8 parts by weight;Biological complex enzyme preparation includes at least three kinds of protease, lipase, cellulase, urease and sulfatase;Probiotic preparation includes at least one of bacillus, lactic acid bacteria, photosynthetic bacteria;Preparation method includes: carrier drying, crushing and sieving, obtain pretreated carrier;Biological complex enzyme preparation, probiotic preparation and auxiliary agent are uniformly mixed to obtain mixed powder;Mixed powder and pretreated carrier are stirred and mixed under normal temperature sterile condition to obtain primary product;Primary product is dried and sieved at low temperature to obtain biological enzyme deodorization antibacterial agent.The application has the advantages that: solve the secondary pollution, short-term effect, poor synergy and complex preparation of existing deodorization antibacterial agent, realize efficient deodorization, long-acting antibacterial and no secondary pollution, and the preparation process is simple, cost controllable.

The invention discloses a method for evaluating electronic waste pollution exposure risk based on a simple function, and the method comprises the following steps: collecting urine of crowds in an electronic waste pollution potential exposure area, centrifuging a urine sample, taking supernate, sequentially adding 1% formic acid, an internal standard solution and a beta-glucuronidase / aryl sulfatase mixed solution, and uniformly stirring; the method comprises the following steps of: performing enzymolysis, extracting and enriching, taking supernate, performing instrumental analysis to obtain the concentrations of 2, 4, 6-TriBP, 2, 4, 5-TriCP and 4-MonoBP in the urine, measuring the concentration of creatinine in the urine, and correcting; constructing three judgment functions, wherein the numbers of the three functions are all 1t; and when 0, judging that the crowd is exposed to the electronic waste. According to the method, geometric visualization and function explicit of decision logic are realized in a mode of combining feature importance analysis and decision boundary projection, and finally three simplified functions which are convenient for practical application and are used for predicting the exposure risk of electronic waste pollution are formed.

The present invention relates to a lyophilized preparation containing, as an active ingredient, a fusion protein of an antibody and heparan N-sulfatase (SGSH), the lyophilized preparation further comprising an isotonic agent, a nonionic surfactant, and a buffering agent, wherein the nonionic surfactant contains polysorbate and poloxamer, and the buffering agent contains histidine.

Certain embodiments provide a fusion protein comprising an iduronate 2-sulfatase (IDS) amino acid sequence, an IDS variant amino acid sequence, or a catalytically active fragment thereof; and an anti-transferrin receptor (TfR) antibody as described herein, as well as methods of use thereof.

Methods and compositions for diagnosing, preventing or treating a viral infection in a subject comprising administering to a subject in need thereof an effective amount of a glycosidase or a sulfatase to degrade a glycan, such as heparan sulfate, to inhibit viral infection, such as COVID-19. Methods for identifying a glycosidase, a sulfatase, or a microbe associated with increased susceptibility to viral infection in a subject.

The invention discloses a rhodococcus strain with broad-spectrum plasticizer degradation capacity and application of the rhodococcus strain for coding alkyl sulfatase. The rhodococcus strain is preserved in China Center for Type Culture Collection on April 27, 2025 with the preservation name of SPR1 and the preservation number of CCTCC NO.M 2025907. The invention further discloses a preparation method of the rhodococcus strain. Gene sequence analysis and identification prove that the strain is rhodococcus fangensis of rhodococcus genus, is named as SPR1, and belongs to gram-positive bacteria. The SPR1 strain is capable of efficiently degrading a plurality of traditional plasticizers (such as dioctyl phthalate) and novel plasticizers (such as trioctyl trimellitate). In addition, the invention discloses the novel carboxyl esterase activity of alkyl sulfatase (named as TOTMAseA) encoded by the strain for the first time, and proves that the enzyme plays a key role in degradation of trioctyl trimellitate. The strain and enzyme gene resources thereof have important research and development values and wide engineering application prospects in the fields of plastic waste treatment and plasticizer polluted environment restoration.

The application discloses a method for evaluating electronic waste pollution exposure risk based on simple functions, which comprises the following steps: collecting urine of people in a potential exposure area of electronic waste pollution, taking supernatant after centrifugation of the urine sample, sequentially adding 1% formic acid, an internal standard solution and a beta-glucuronidase / arylsulfatase mixed solution, extracting and enriching after enzymolysis, taking supernatant for instrument analysis, obtaining the concentrations of 2,4,6-TriBP, 2,4,5-TriCP and 4-MonoBP in the urine, simultaneously determining the concentration of creatinine in the urine and performing correction; three judgment functions are constructed, and when the values of the three functions are all less than 0, it is determined that the people are exposed to electronic waste. Through the combination of feature importance analysis and decision boundary projection, geometric visualization and function explicitness of the decision logic are realized, and finally three simple functions for predicting the electronic waste pollution exposure risk are formed, which are convenient for practical application.

Certain embodiments provide a fusion protein comprising an iduronate 2-sulfatase (IDS) amino acid sequence, an IDS variant amino acid sequence, or a catalytically active fragment thereof; and an anti-transferrin receptor (TfR) antibody as described herein, as well as methods of use thereof.

This invention relates to viral vectors for delivery of iduronate-2-sulfatase (IDS) to a subject. In some aspects the IDS sequence is optimized for expression in human cells. The invention further relates to methods of using the vector to increase secretion of IDS from a cell and for treatment and prevention of mucopolysaccharidosis II.

Disclosed herein are methods for treating and / or preventing a protein-aggregation disease by administering a sulfatase inhibitor to a subject.

The invention provides a heparinase detection method which comprises the following steps: a) diluting each reference substance of heparinase and a 2-O-sulfatase reference substance with a diluent to prepare reference substance solutions with certain concentrations, and recording the enzyme concentrations of the reference substance solutions as Cref-HepI, Cref-HepII, Cref-HepIII and Cref-2O respectively; b) determining the reference substance solution obtained in the step a) by adopting a high performance liquid chromatography method, recording retention time and peak area, and respectively recording the peak area of each enzyme as Aref-HepI, Aref-HepII, Aref-HepIII and Aref-2O; c) diluting a heparinase sample to be detected with a diluent to prepare a heparinase test solution with a certain concentration; d) determining the retention time and the peak area of each enzyme in the heparinase test solution by adopting a high performance liquid chromatography method, and respectively recording the peak areas of each enzyme in the test solution as A < supply >-HepI, A < supply >-HepII, A < supply >-HepIII and A < supply >-2O; and e) calculating the purity and the concentration according to a formula. The detection method can simultaneously detect heparinase I, heparinase II, heparinase III and impurity enzymes, and is simple, convenient, rapid and accurate to operate.

The present invention is related to a method for purifying heparan-N-sulfatase from a heparan-N-sulfatase-containing solution including at least one impurity, the method comprising performing multi-mode chromatography (MMC) to obtain an eluate; and performing caprylate precipitation to obtain a supernatant.The method according to the present invention is capable of very efficiently removing HCP (host cell proteins) and of greatly improving the purity and stability of purified heparan-N-sulfatase.

Applicants sought to express human iduronate-2-sulfatase (hIDS) in the brain endothelium of a mouse model of Mucopolysaccharidosis type II (MPSII, Hunter's syndrome) to enable enzyme secretion into the brain parenchyma. In this disorder, IDS deficiency results in the pathophysiological accumulation of heparan and dermatan sulfate GAGs. To test the hypothesis, Applicants chose AAV-BI30, an AAV9-derived capsid that has an enhanced in vivo tropism specific to the endothelium in the rodent CNS and can transduce human brain vascular endothelial cells in vitro more efficiently than AAV9. Applicants show that systemic delivery of AAV-BI30: hIDS restored IDS enzyme activity in the brain, liver, and serum of IDS-KO mice (FIG. 1). Importantly, AAV-BI30-mediated gene transfer resulted in the correction of GAG accumulation in the brain (FIG. 2). This effect was not observed when using the AAV-BI30 vector packaging a non-secreting version of hIDS. These findings highlight that targeting endothelial cells throughout the CNS is a promising approach for delivering enzymes across the BBB and restoring lysosomal metabolism.

The present disclosure provides methods and formulations for treating or preventing mucopolysaccharidosis II (MPS II) related hearing loss using recombinant human iduronate-2-sulfatase (IDS).

Provided is a recombinant adeno-associated virus (rAAV) having an AAVhu68 capsid and a vector genome which comprises a nucleic acid sequence encoding a functional human arylsulfatase A (ARSA). Also provided are a production system useful for producing the rAAV, a pharmaceutical composition comprising the rAAV, and a method of treating a subject having metachromatic leukodystrophy, or ameliorating symptoms of metachromatic leukodystrophy, or delaying progression of metachromatic leukodystrophy via administrating an effective amount of the rAAV to a subject in need thereof.

A paper-based analytical device for potentiometric assay of Arylsulfatase A (ARSA) activity levels. The analytical device comprises a filter paper substrate supporting a potentiometric cell, a reference electrode, and an ion-selective electrode. The electrodes are constructed using an ink comprising carbon nanotubes and reduced graphene oxide (r-GO). The analytical device also includes a solid-contact potentiometric sensor for ARSA integrated with the electrodes and a polymeric membrane associated with the ion-selective electrode. The analytical device is capable of providing results from actual serum and whole blood samples. A method for monitoring blood ARSA levels and a method for fabricating the analytical device are also disclosed.